IXICO plc

("IXICO", the "Company" or the "Group")

IXICO appoints Chief Commercial Officer to accelerate business development activity and broaden US footprint

-Tanya Voloshen, CCO joins IXICO as a member of the Senior Leadership Team with deep commercial and executive leadership experience in the neuroimaging market -

05 February 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has appointed Tanya Voloshen as Chief Commercial Officer (CCO) based in Boston, Massachusetts (USA).

Tanya joins IXICO from Perceptive Inc. a global contract research organisation (CRO) where she held the role as SVP Commercial.  Prior to joining Perceptive, Tanya held senior commercial leadership roles for international clinical trial and medical technology companies with a focus on neuroscience and medical imaging including Clario (now part of Thermo Fisher Scientific), QMENTA and ConcertAI. Tanya started her career in the pharmaceutical industry working for Johnson & Johnson and Sanofi.             

Bram Goorden, Chief Executive Officer of IXICO, commented: "I am very pleased to welcome Tanya to IXICO as CCO, a newly appointed position in the senior leadership team that reflects a firm and continued commitment to strengthen our commercial capabilities and accelerate growth. Based in Boston, Tanya brings strong commercial leadership experience, established customer relationships and an excellent understanding of the critical contribution that IXICO's technology platform can make in the clinical imaging market."        

Ends

For further information please contact:

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.   As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.  

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.